- Home
- SLNH vs FBRX Comparison
SLNH vs FBRX Comparison
Compare SLNH & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLNH | FBRX |
|---|---|---|
| Founded | 1961 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.8M | 170.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SLNH | FBRX |
|---|---|---|
| Price | $1.95 | $20.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 4.7M | 108.3K |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,782,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $42.68 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $4.90 |
| 52 Week High | $5.14 | $26.40 |
Technical Indicators
Market Signals| Indicator | SLNH | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 63.34 |
| Support Level | $1.55 | $18.85 |
| Resistance Level | $1.91 | $21.45 |
| Average True Range (ATR) | 0.23 | 2.12 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 96.55 | 55.30 |
Price Performance
Historical ComparisonAbout SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).